Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morie Gertz

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 20, 2025
Proteomic determinants of renal organ response in light-chain amyloidosisMatthew J Rees, Eli Muchtar, Suheil-Albert Atallah-Yunes, et al.
Bone Marrow Transplantation|October 6, 2022
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myelomaCharalampos Charalampous, Utkarsh Goel, Morie Gertz, et al.
European Journal of Neurology|March 31, 2026
Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform TrialJulian D Gillmore, David Adams, Markus Weiler, et al.
Muscle & Nerve|April 6, 2026
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female PatientsMárcia Waddington Cruz, John L Berk, Yeşim Parman, et al.
Haematologica|July 24, 2025
Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodiesMatthew J Rees, Surendra Dasari, Ellen D McPhail, et al.
World Journal of Transplantation|July 1, 2016
Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experienceMartha Grogan, Morie Gertz, Arleigh McCurdy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to S. Girnius et alGiovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
Muscle & Nerve|November 18, 2024
Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin AmyloidosisFolke Folkvaljon, Morie Gertz, Julian D Gillmore, et al.
European Heart Journal|December 25, 2004
Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniquesKaren M Modesto, Angela Dispenzieri, Sanderson A Cauduro, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 20, 2025
Proteomic determinants of renal organ response in light-chain amyloidosisMatthew J Rees, Eli Muchtar, Suheil-Albert Atallah-Yunes, et al.
Bone Marrow Transplantation|October 6, 2022
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myelomaCharalampos Charalampous, Utkarsh Goel, Morie Gertz, et al.
European Journal of Neurology|March 31, 2026
Effect of Eplontersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Across Genetic Variants: An Exploratory Analysis From the NEURO-TTRansform TrialJulian D Gillmore, David Adams, Markus Weiler, et al.
Muscle & Nerve|April 6, 2026
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female PatientsMárcia Waddington Cruz, John L Berk, Yeşim Parman, et al.
Haematologica|July 24, 2025
Proteomic shifts post plasma cell therapy in AL amyloid plaques and potential implications for light chain directed anti-fibril monoclonal antibodiesMatthew J Rees, Surendra Dasari, Ellen D McPhail, et al.
World Journal of Transplantation|July 1, 2016
Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experienceMartha Grogan, Morie Gertz, Arleigh McCurdy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2013
Reply to S. Girnius et alGiovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
Muscle & Nerve|November 18, 2024
Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin AmyloidosisFolke Folkvaljon, Morie Gertz, Julian D Gillmore, et al.
European Heart Journal|December 25, 2004
Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniquesKaren M Modesto, Angela Dispenzieri, Sanderson A Cauduro, et al.
Pageof 12